ICON Public (NASDAQ:ICLR) Issues FY25 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $13.00-15.00 for the period, compared to the consensus estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Price Performance

Shares of ICON Public stock opened at $199.47 on Thursday. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The company has a market cap of $16.46 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.59 and a beta of 1.20. The firm has a fifty day moving average price of $210.79 and a two-hundred day moving average price of $270.01. ICON Public has a fifty-two week low of $183.38 and a fifty-two week high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing the consensus estimate of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to the consensus estimate of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $3.10 earnings per share. Analysts expect that ICON Public will post 13.41 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ICLR. Truist Financial reaffirmed a “buy” rating and set a $284.00 price target (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. The Goldman Sachs Group lowered their target price on ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. StockNews.com lowered shares of ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Finally, Barclays dropped their target price on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.